|
WINNIPEG, Manitoba – January 22, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today the successful completion of testing to characterize the performance of its P2V™ test in an immunoassay format. The results confirmed the test’s diagnostic performance as a biopsy screening tool providing a 91% sensitivity with a 25% specificity. These results are statistically similar in performance to the mass spectrometry assay results which earlier reported the test performing with a 93% sensitivity and a 23% specificity. The P2V™ test is a patent pending combination of two markers, PSP94 and a fragment of vitronectin, for use as a biopsy screen tool for patients with prostate cancer.
Read More
|
|
WINNIPEG, Manitoba – December 31, 2008 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $232,500 from the sale of 4,650,000 units ("Units") at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. The net proceeds of the Offering shall be used for research and development and working capital purposes. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
Read More
|
|
WINNIPEG, Manitoba – December 23, 2008 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on November 10, 2008. The Company is amending the Offering to sell up to 6,000,000 units ("Units") at a price of $0.05 per Unit for gross proceeds of up to $300,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. All other terms of the Offering remain the same.
Read More
|
|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 4,500,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $315,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 18 months from the date the Warrant is issued.
Read More
|
|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce the enrollment of its first patient in the second pivotal study for the Company’s P2V™ prostate cancer diagnostic test. The study will be conducted at the Winnipeg Clinic under the guidance of Principal Investigator, urologist, Dr. Patrick Cho. Samples collected from the study will be tested using recently developed Luminex based assays for both PSP94 and Vitronectin, the two proteins that form the P2V™ test.
Read More
|
|
|